FDA lifts pause on IXCHIQ for adults ≥60 and approves new label warnings

What happened—quick timeline

May 9, 2025: FDA and CDC recommended a pause in use of IXCHIQ for people ≥60 years while they investigated post-marketing reports of serious neurologic and cardiac events, including deaths, following vaccination. U.S. Food and Drug Administration GovDelivery
Aug 6–7, 2025: After a fresh benefit–risk assessment, FDA removed the recommended pause and approved required updates to the Prescribing Information (PI) and Patient Information for IXCHIQ (sponsor: Valneva Austria GmbH). U.S. Food and Drug Administration+1

Why the concern in the first place?

IXCHIQ is a live, attenuated chikungunya vaccine; it can produce chikungunya-like symptoms. FDA’s case review included serious adverse events in older adults, some consistent with severe complications of chikungunya disease (e.g., encephalitis). One death from encephalitis was specifically noted in FDA’s safety communication, and earlier counts cited 17 serious AEs (ages 62–89), two deaths, many with underlying conditions. U.S. Food and Drug Administration+1

What’s new on the label (August 2025)?

FDA’s updated, official PI (revised 08/2025) highlights several major changes: U.S. Food and Drug Administration

Indications & Limitations of Use (Section 1):
- Vaccine is indicated for adults ≥18 at high risk of exposure.
- “Vaccination with IXCHIQ is not advisable for most U.S. travelers,” because exposure risk is usually low; decisions should weigh exposure risk vs. risks of serious, severe, or prolonged chikungunya-like illness from the vaccine. U.S. Food and Drug Administration
Contraindications (Section 4):
- Do not administer to immunocompromised individuals (disease, therapy, etc.). U.S. Food and Drug Administration
Warnings & Precautions (Section 5.2):
- Explicit warning that IXCHIQ may cause serious, severe, or prolonged chikungunya-like illness; trial rate of severe illness 1.6% (2 hospitalizations).
- Postmarketing: serious illness requiring hospitalization, including a fatal encephalitis case.
- Signal in older adults: limited data suggest people ≥65 with one or more chronic conditions may have an increased risk of serious chikungunya-like illness after vaccination. U.S. Food and Drug Administration
Pregnancy/vertical transmission (Section 5.3 & 8.1):
- Vaccine viremia occurs in the first week post-dose, resolving by day 14; unknown if vaccine virus can be vertically transmitted. Neonates born within 14 days of maternal vaccination should be closely monitored for 7 days post-birth. U.S. Food and Drug Administration
Adverse reactions (Sections 6.1, 6.2):
- Most common systemic reactions: headache (31.6%), fatigue (28.5%), myalgia (23.9%), arthralgia (17.2%), fever (13.5%), nausea (11.2%). U.S. Food and Drug Administration

FDA’s action—what exactly did the Agency do?

Concluded an updated benefit–risk assessment (all adults ≥18, with focused analysis for ≥60).
Removed the recommended pause for ≥60 years.
Required and approved updates to the Prescribing Information and Patient Information to clarify who should get the vaccine and how to manage key risks.
Reiterated post-marketing surveillance via VAERS and ongoing safety monitoring. U.S. Food and Drug Administration

FDA’s public notice explicitly states the pause has been removed and the labeling has been updated; content was current Aug 7, 2025. U.S. Food and Drug Administration

Practical guidance for vaccinators & clinicians

Before vaccination

Assess exposure risk (destination disease activity, duration of travel/residence, mosquito exposure) and patient factors (age, comorbidities, pregnancy plans). For most U.S. travelers, do not vaccinate unless exposure risk is genuinely high. U.S. Food and Drug Administration
Screen out: immunocompromised patients; postpone around pregnancy when possible; counsel those ≥65 with chronic conditions about potentially higher risk. U.S. Food and Drug Administration

Counseling points

Explain chikungunya-like illness can occur after vaccination (rarely serious/prolonged)—watch for fever, severe myalgia/arthralgia, neurologic symptoms in the first 2 weeks post-dose; seek care if severe. U.S. Food and Drug Administration
Discuss expected reactogenicity (headache, fatigue, myalgia, arthralgia, fever, nausea). U.S. Food and Drug Administration

Pregnancy & neonates

If vaccination occurs during pregnancy near term, monitor neonate for 7 days if birth occurs within 14 days of maternal vaccination. U.S. Food and Drug Administration

Reporting

Report suspected AEs to VAERS (co-managed by FDA/CDC). U.S. Food and Drug Administration

What manufacturers need to consider or revise (actionable checklist)

Labeling & materials

Implement the FDA-approved PI/Patient Information updates (Aug 2025) without delay across USPI PDFs, carton inserts, websites, and digital copies. Include:
- Prominent Limitations of Use (“not advisable for most U.S. travelers”).
- Contraindication for immunocompromised individuals.
- Expanded Warnings (5.2) on serious/severe/prolonged chikungunya-like illness, postmarketing fatal encephalitis, and the older-adult risk signal.
- Pregnancy/vertical transmission guidance and neonatal monitoring. U.S. Food and Drug Administration

Medical affairs & HCP communications

Issue Dear Health Care Provider letters and updated vaccination decision aids that emphasize:
- Risk stratification in ≥65 with chronic conditions.
- Exposure-risk decision tree for travelers (link to CDC traveler risk resources). U.S. Food and Drug Administration
Refresh patient handouts to reflect who should/shouldn’t get IXCHIQ and what to watch for post-vaccine. U.S. Food and Drug Administration

Pharmacovigilance

Enhance signal detection for terms aligned to chikungunya-like illness (encephalitis, severe myalgia/arthralgia, neurologic/cardiac events) and age-comorbidity interactions; expedite medically significant cases.
Continue proactive VAERS/FAERS monitoring, periodic benefit–risk updates to FDA; incorporate age-stratified analyses. U.S. Food and Drug Administration

Clinical & operational

Update EHR order sets and screening checklists (immunocompromised status, pregnancy timing, age ≥65 + comorbidities, traveler risk).
Retrain vaccination staff on reconstitution/administration and post-vaccination observation, including recognition of serious chikungunya-like illness. (PI Sections 2, 5). U.S. Food and Drug Administration

Global context (for multinational teams)

Regulators in Europe and the UK temporarily restricted use in older adults earlier in 2025 and have since adjusted positions as reviews concluded; align communications across regions accordingly. Managed Healthcare Executive Reuters ContagionLive Vaccine Advisor

What this means for travelers & public health

Who still benefits? Adults at high risk of exposure (e.g., long-term stays in endemic areas, outbreak regions, certain lab workers). For these groups, vaccine protection against a debilitating disease can outweigh risks—but careful screening and counseling are essential. U.S. Food and Drug Administration
For most U.S. travelers, stick to mosquito-avoidance measures unless exposure risk is clearly elevated; the label now explicitly discourages routine use. U.S. Food and Drug Administration

Key facts at a glance

Topic	FDA/Label Takeaway
Status (Aug 2025)	Pause lifted for ≥60 after updated benefit–risk review; label updated. U.S. Food and Drug Administration
Who to vaccinate	Adults ≥18 at high exposure risk; not advisable for most U.S. travelers. U.S. Food and Drug Administration
Do not vaccinate	Immunocompromised individuals; history of severe allergy to components. U.S. Food and Drug Administration
Major warning	Serious/severe/prolonged chikungunya-like illness; rare fatal encephalitis post-marketing. Possible higher risk in ≥65 with chronic conditions. U.S. Food and Drug Administration
Pregnancy & neonates	Vaccine viremia ≤14 days; if delivery occurs within 14 days of maternal dose, monitor neonate 7 days. U.S. Food and Drug Administration
Common reactions	Headache, fatigue, myalgia, arthralgia, fever, nausea. U.S. Food and Drug Administration
Reporting	VAERS for suspected adverse events. U.S. Food and Drug Administration

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.